Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
920 Views
Dr Anil Bharani, Indore 19 December 2017
It is indicated to reduce the risk of CV death and hospitalization for heart failure in patients with HFrEF (NYHA Class II-IV). As per the ACC/AHA and ESC Guidelines 2016, replacement by an ARNi is recommended in patients with chronic symptomatic HFrEF NYHA Class II or III who tolerate an ACEI or ARB, to further reduce morbidity and mortality.
ARNi should not be co-administered with ACEI or within 36 hours of the last dose of an ACEI because of risk of angioedema and should not be administered to patient with a history of angioedema. Hypotension, angioedema, worsening renal functions and hyperkalemia are infrequent untoward effects.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}..
High 1-hour Plasma Glucose: Early Indicator of Type 2 Diabetes Risk..
Maintaining Liver Health to Optimize Glycemic Outcomes in Early Type 2.....
Antibiotic Prescribing Practices for Pediatric Acute Otitis Media..
Hidden Hazard of Indoor Pollution in COPD..
Recognizing Pitfalls of Point-of-Care Lung Ultrasound..
{{Article_Title}}..
HMPV in India: Seven Cases Reported across Four States..
West Bengal Commission Fines Divine Nursing Home Rs 10 Lakh for Medical Negligence..
India Reports First Human Metapneumovirus (HMPV) Cases in Karnataka..
Two-Year-Old Dies after Wrong Injection Administered by Private Compounder in Jaisalmer..
'Law of the Land' Paramount for Blinkit's Ambulance Services, Says PiyushGoyal..